Generation Bio Co., a genetic medicines company, develops gene therapies for the treatment of rare and prevalent diseases. The company is developing a portfolio of programs for rare and prevalent diseases of the liver and retina. It also focuses on the diseases of skeletal muscle, central nervous system, and oncology. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
IPO Year: 2020
Exchange: NASDAQ
Website: generationbio.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/19/2023 | Outperform → Market Perform | TD Cowen | |
| 11/8/2022 | $9.00 | Buy | Canaccord Genuity |
| 12/15/2021 | $40.00 → $10.00 | Market Outperform | JMP Securities |
| 12/15/2021 | $50.00 → $27.00 | Buy | Needham |
| 12/14/2021 | Outperform → Mkt Perform | William Blair |
8-K - Generation Bio Co. (0001733294) (Filer)
S-8 - Generation Bio Co. (0001733294) (Filer)
10-Q - Generation Bio Co. (0001733294) (Filer)
8-K - Generation Bio Co. (0001733294) (Filer)
DEFA14A - Generation Bio Co. (0001733294) (Filer)
DEF 14A - Generation Bio Co. (0001733294) (Filer)
10-K - Generation Bio Co. (0001733294) (Filer)
8-K - Generation Bio Co. (0001733294) (Filer)
8-K - Generation Bio Co. (0001733294) (Filer)
SCHEDULE 13G/A - Generation Bio Co. (0001733294) (Subject)